Journal of Clinical Medicine
Association of Serum Visfatin Levels with Coronary Artery Disease and Biochemical Parameters in Patients Undergoing Maintenance Hemodialysis
By Nimet Aktaş, Mustafa Güllülü, Nur Özer Şensoy and 2 others.
Abstract
Background
Cardiovascular disease is a major cause of morbidity and mortality in patients with end-stage kidney disease receiving maintenance hemodialysis. Visfatin is a pro-inflammatory adipokine involved in metabolic and inflammatory pathways; however, its relationship with established coronary artery disease (CAD) in hemodialysis patients remains uncertain. This study evaluated the associations of serum visfatin concentrations with hemodialysis status, clinically documented CAD, and selected metabolic and biochemical parameters.
Methods
This cross-sectional study included 130 non-diabetic adults classified into four groups: healthy controls (n = 40), participants with preserved renal function and established CAD (n = 28), maintenance hemodialysis patients without CAD (n = 30), and maintenance hemodialysis patients with established CAD (n = 32). Demographic, anthropometric, and laboratory variables were recorded. Serum visfatin concentrations were measured using an enzyme-linked immunosorbent assay. Between-group comparisons and exploratory correlation analyses were performed. Analysis of covariance was additionally used to assess between-group differences in visfatin after adjustment for age, sex, hypertension, and BMI, with body fat percentage substituted for BMI in a sensitivity analysis.